AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
18.6.2020 03:00:00 EEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 09:05:00 EET | Press release
EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to renewable energy, stable power grid, technical workforce and strong sustainability framework alig
Lyten Completes Acquisition of Northvolt Sweden and Establishes its First Lyten Industrial Hub in Sweden27.2.2026 09:00:00 EET | Press release
Lyten, a global leader in lithium-sulfur batteries and energy storage, announced today that it has completed the acquisition of Northvolt Ett and Ett Expansion (Skellefteå, Sweden) and Northvolt Labs (Västerås, Sweden). The Northvolt Sweden acquisition includes 16 GWh of existing battery manufacturing capacity, more than 160 hectares of land, infrastructure and buildings to support expanded manufacturing and industrial activities, and the largest and most advanced battery research and development center in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226538293/en/ Northvolt Labs, the largest battery research and development facility in Europe. Located in Västerås, Sweden. Lyten additionally announced the formation of the Lyten Industrial Hub, located in Skellefteå, at the Northvolt Ett site. The industrial hub will utilize the infrastructure built by Northvolt and access to abundant, clean hydro power to co-loca
SOLUM and Competera Expand Partnership to Integrate AI-Driven Pricing Solutions with Real-Time ESL Execution Across Europe27.2.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Competera announced the expansion of their strategic partnership to further connect AI-driven pricing intelligence with real-time Electronic Shelf Label (ESL) execution across European retail networks. The announcement follows strong engagement at EuroShop, where the integrated solution attracted significant interest from the local retail operators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226065052/en/ SOLUM and Competera announced the expansion of their strategic partnership (Image: SOLUM) The collaboration brings together Competera’s AI-driven pricing solutions for enterprise retail with SOLUM’s Newton ESL platform, enabling retailers to align advanced price optimization with synchronized shelf-edge communication. Competera’s platform applies machine learning and advanced analytics to help retailers balance competitiveness and value-based pricing, strengthen customer loyalty, improve pri
OpenSynergy's Blue SDK Now Drives More Than 400 Million Cars27.2.2026 09:00:00 EET | Press release
OpenSynergy's Blue SDK, the industry-leading independent Bluetooth® stack, is now deployed in over 400 million cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226654887/en/ OpenSynergy's Blue SDK now drives more than 400 million cars OpenSynergy is thrilled and very proud to announce that Blue SDK is now integrated in more than an estimated 400 million cars worldwide, deployed by virtually all the major OEMs across a wide range of vehicles, segments, and markets, offering extensive and consistent interoperability between many generations of smartphones and cars. “This is an incredible milestone for OpenSynergy, but it is also a testament to the ubiquity of the Bluetooth standard in our everyday lives and the success of the entire Bluetooth ecosystem under the leadership of the Bluetooth SIG,” comments Kathleen Ende, CEO, OpenSynergy. “Blue SDK is now an essential part of the daily automotivecockpit plug and play expe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom